• Bleomycin Sulfate in Fibrosis Assay Design

  2026-09-07

  Bleomycin Sulfate is more than a DNA damage reagent: it can anchor a staged workflow linking injury induction to macrophage-targeted fibrosis interventions. This article explains how to design, interpret, and translate such assays using mechanistic and delivery-focused evidence.

• Extra-Helical Binding of the GCGR Antagonist MK 0893

  2026-09-07

  The reference study solved a 2.5 Å structure of human glucagon receptor bound to MK 0893, revealing an unexpected allosteric pocket outside the seven-transmembrane bundle. This finding explains how the antagonist may block receptor activation and provides a structural framework for glucagon receptor antagonist discovery in type 2 diabetes research.

• MK-571 (L-660,711) Assay Guide

  2026-09-05

  This scenario-based guide explains how MK-571 (L-660,711), SKU B7023, can be used thoughtfully in leukotriene, viability, cytotoxicity, and MRP1-related experiments. It connects formulation control, assay design, and interpretation of macrophage protection data to practical laboratory decisions.

• Okadaic acid: PP1/PP2A Workflow Guide

  2026-09-04

  Okadaic acid (SKU A4540) provides concentration-dependent PP2A and PP1 inhibition for biochemical phosphatase assays and phosphorylation-linked cell studies. This guide covers handling, controls, and interpretation for apoptosis assay workflows; biochemical IC50 values are not universal cellular doses, and use is inappropriate when phosphatase selectivity or solvent exposure cannot be controlled.

• Preserving Phosphorylation in Proteostasis Research

  2026-09-04

  A translational perspective on how phosphatase control strengthens SIRT6, proteostasis, and neurodegeneration workflows.

• GM 6001: From MMP Inhibition to PNN Biology

  2026-09-03

  GM 6001 (Galardin) offers a powerful way to interrogate MMP-dependent extracellular matrix remodeling. This article connects its broad-spectrum activity to perineuronal-net biology, Alzheimer’s disease models, and better causal assay design.

• Tubeimoside I: ATP1A1-Targeted Senolysis in Aging

  2026-09-03

  A 2026 Phytomedicine study identifies tubeimoside I as a senolytic that preferentially eliminates senescent cells by targeting ATP1A1 and disrupting potassium-dependent ion homeostasis. Its combined in vitro and mouse-model evidence links ATP1A1 modulation to mitochondrial apoptosis, reduced senescence markers, and improved aging-associated outcomes, while also highlighting the need for orthogonal validation beyond metabolic viability assays.

• Mechanical Stress, Autophagy, and the Cytoskeleton

  2026-09-02

  The reference study provides direct evidence that compressive mechanical stress induces autophagy through a cytoskeleton-dependent process, with microfilaments serving as the principal structural component and microtubules making a supporting contribution. Its combination of cytoskeletal polymerization perturbation, fluorescence imaging, and western blotting offers a practical framework for studying how physical forces are converted into autophagic responses.

• Fludarabine: From DNA Synthesis to Assay Design

  2026-09-02

  Explore how Fludarabine, a DNA synthesis inhibitor, connects purine-analog biochemistry with rigorous oncology assay design. This guide adds a genotype-aware interpretation framework inspired by Waldenström macroglobulinemia therapy-sequencing research.

• Lanabecestat (AZD3293): Smarter BACE1 Assays

  2026-09-01

  Explore how Lanabecestat (AZD3293) supports mechanistically informed BACE1 assays, from amyloid-beta production inhibition to functional neuronal readouts. This article translates key findings from Satir et al. into practical experimental design and interpretation guidance.

• Propidium Iodide Workflows for Granulosa Cell Assays

  2026-09-01

  Propidium iodide converts membrane damage and DNA content into measurable fluorescence, making it a practical complement to CCK-8, Western blotting, and Annexin V in granulosa-cell research. This workflow translates AMH–SMAD4 findings in PCOS rats into actionable viability, apoptosis, and cell-cycle experiments.

• MK 0893: Glucagon Receptor Antagonist Workflows

  2026-08-31

  Build more interpretable GCGR binding and cAMP assays with MK 0893, a potent competitive reversible antagonist suited to receptor pharmacology and glucose-regulation studies. The workflow connects nanomolar cellular activity with practical solvent handling, selectivity controls, and translational testing in hGCGR animal models.

• Mitomycin C: From DNA Damage to Immune-Ready Models

  2026-08-31

  Mitomycin C is more than a conventional cytotoxic benchmark. As an antitumor antibiotic that forms covalent DNA adducts, it gives translational researchers a controllable way to study DNA replication inhibition, apoptosis priming, and TRAIL sensitization. This article connects those established applications with a recent HCC immunotherapy study while clearly separating validated evidence from hypothesis-generating opportunities.

• Triterpene Prodrug Enables Self-Boosted OSCC Therapy

  2026-08-30

  This 2024 ACS Applied Materials & Interfaces study developed a carrier-free, self-assembled prodrug from glycyrrhetinic acid and ginsenoside Rh2 for oral squamous cell carcinoma. Its ROS-responsive design couples tumor-associated uptake with a feedback mechanism in which glycyrrhetinic acid amplifies oxidative stress and promotes further drug release, offering a preclinical strategy for reducing reliance on complex nanocarriers.

• QRICH1, HMGB1, and HBV-Driven Liver Fibrosis

  2026-08-29

  The 2025 Immunobiology study identifies QRICH1 as an endoplasmic reticulum stress effector that strengthens HBV-associated HMGB1 transcription, acetylation-related translocation, and secretion. By integrating a chronic rcccDNA mouse model with clinical hepatitis B specimens, the work connects viral stress signaling to inflammatory and fibrotic liver injury while highlighting important limits on causal interpretation.

8599 records 6/574 page Previous Next First page 上5页 678910 下5页 Last page